Top Abstract Purchase Related
Home
>
Node
>
Subnode

Efficiency of remaxol in preventing unwanted side effects of the antiviral therapy in patients with chronic hepatitis C

Baranova, I.P.; Zykova, O.A.; Krasnova, L.I.; Romantsov, M.G.; Nikol'skaia, M.V.; Aftaeva, L.N.

Eksperimental'naia i Klinicheskaia Farmakologiia 76(11): 44-46

2013

ISSN/ISBN: 0869-2092
PMID: 24555234
Document Number: 666857
The article briefly addresses issues pertaining to the problem of complications encountered in antiviral therapy of patients with chronic hepatitis C. Data on the effectiveness of remaxol as a means of preventing the development of complication in patients with chronic viral hepatitis C in early stages of antiviral treatment.

Document emailed within 1 workday
Secure & encrypted payments

Selivestrova, T.R.; Trufanova, I.M.; Morozov, S.V.; Isakov, V.A. 2011: Indicators of body composition as prognostic factors of efficiency of antiviral therapy for chronic hepatitis C Eksperimental'naia i Klinicheskaia Gastroenterologiia 1: 54-58
Arase, Y. 2006: Side effects of interferon therapy for chronic hepatitis C Nihon Rinsho. Japanese Journal of Clinical Medicine 64(7): 1363-1367
Lopukhova, N.L. 2007: Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases Eksperimental'naia i Klinicheskaia Gastroenterologiia 4: 146-152
Vcev, A. 2009: Management of side effects during antiviral therapy Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 63(5): 463-467
Dong, Y.; Zhang, H.-f.; Chen, H.; Li, J.; Yang, X.-j.; Zhu, S.-s.; Cheng, Y. 2008: Level of the cytokine secreted by periferal blood mononuclear cells in patients with chronic hepatitis C before antiviral therapy Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 22(5): 364-366
Xu, D.-Z.; Xie, Y.; Li, Z.-Q. 2005: Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C Hepatobiliary and Pancreatic Diseases International: Hbpd Int 4(4): 550-553
Fedorchenko, S.V. 1994: Can chronic hepatitis B patients overcome resistance to antiviral therapy due to production of antibodies to recombinant alpha-2-interferon? Voprosy Virusologii 39(5): 218-220
Gwak, G-Youn.; Kim, T.Hun.; Yu, S.Jong.; Yoon, J-Hwan.; Yong, J.Jung.; Park, S.Cheol.; Lee, H-Suk. 2007: Lack of association between serum leptin levels and hepatic steatosis, fibrosis or response to antiviral therapy in Korean chronic hepatitis C patients Hepato-Gastroenterology 54(75): 844-848
Schnabel, A.; Reinhold-Keller, E.; Willmann, V.; Dihlmann, W.; Gross, W.L. 1994: Side effects and efficiency of 15 mg and 25 mg methotrexate per week in chronic polyarthritis Zeitschrift für Rheumatologie 53(3): 142-149
Geller, L.I. 1990: Antiviral preparations in the therapy of chronic viral hepatitis Terapevticheskii Arkhiv 62(11): 15-19
Zhdanov, K.V.; Gusev, D.A.; Kozlov, K.V.; Shishkin, M.K.; Sukachev, V.S.; Shakhmanov, D.M.; Zhabrov, S.S. 2015: Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C Voenno-Meditsinskii Zhurnal 336(4): 44-49
Pavelkina, V.F.; Ampleeva, N.P. 2014: Comparative effectiveness hepatotropic activity remaxol and Essentiale N in chronic viral hepatitis Eksperimental'naia i Klinicheskaia Farmakologiia 77(12): 17-21
Muñoz, A.E. 2007: New strategies for a better use of peginterferon and ribavirin and new drugs with specifically-targeted antiviral therapy for chronic hepatitis C Acta Gastroenterologica Latinoamericana 37(2): 126-133
Tung, H.-D.; Lu, S.-N.; Lee, C.-M.; Wang, J.-H.; Chen, T.-M.; Hung, C.-H.; Huang, W.-S.; Changchien, C.-S. 2002: Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay Journal of Viral Hepatitis 9(4): 304-308
Liu, D.; Wen, X.; Meng, Q. 1998: An observation on antiviral effect of IFN--alpha N1 (Wellferon) in patients with chronic hepatitis B Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 12(2): 125-128
Ono, S.K.; da Silva, L.C.; Carrilho, F.J.; da Fonseca, L.E.; Mendes, L.C.; Madruga, C.L.; Farias, A.d.Q.; Laudanna, A.A. 1996: Clearance of hepatitis C viral RNA in cirrhotic patients with antiviral therapy Revista do Hospital das Clinicas 51(5): 180-183
Hige, S.; Matsushima, T.; Karino, Y.; Toyota, J. 1995: Long-term prognosis of patients with chronic hepatitis B from the standpoint of the effects of IFN therapy Nihon Rinsho. Japanese Journal of Clinical Medicine 53 Suppl (Part 2): 594-599
Pinto, A.; Parini, P.; Novelli, V.; Zagari, M.; Sangermano, A.; Orsini, M.; Salzetta, A.; Buffarini, F.; Roda, E. 1992: Effects of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodium salt in patients with chronic hepatitis Minerva Medica 83(6): 359-361
Mathias, B.; Piper, C.; Lasek, R. 1990: Goals and limits of spontaneous detection of unwanted drug side effects Der Internist 31(7): 448-455
Dölle, W.; Daiss, W. 1988: Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects Verhandlungen der Deutschen Gesellschaft für Innere Medizin 94: 184-191